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Abstract 
The hepatic and renal microsomal glucose-6-phosphatase enzymes are situated with their active site in the lumen of the endoplasmic 
reticulum and for normal enzyme activity in vivo transport systems are needed for the substrates and products of the enzyme. We have 
shown that thyroxine activates the kidney glucose-6-phosphatase enzyme and the liver glucose 6-phosphate ransport systems. In contrast, 
in hypophysectomised and adrenalectomised animals, thyroxine activates the transport systems and the enzyme in both liver and kidney. 
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1. Introduction 
Glucose is the primary energy source for most mam- 
malian cells and tissues. Most tissues cannot make signifi- 
cant amounts of glucose, and it is therefore important that 
blood glucose levels are maintained within a narrow range. 
The liver (and to a lesser extent, the kidney) plays an 
important role in blood glucose homeostasis [1,2]. When- 
ever blood glucose levels fall, e.g., between meals, after 
exercise and at times of stress or increased metabolic rate, 
the liver rapidly releases glucose into the bloodstream via 
the plasma membrane transport protein, GLUT2, for use 
by other tissues, e.g., [2,3]. The liver can produce glucose 
via two pathways, gluconeogenesis and glycogenolysis, 
which have a common terminal step catalysed by microso- 
mal glucose-6-phosphatase (EC 3.1.3.9) [1,2]. The hepatic 
glucose-6-phosphatase enzyme is on the lumenal side of 
the endoplasmic reticulum [4-6] which makes in vivo 
glucose-6-phosphatase ctivity dependent on endoplasmic 
reticulum transport systems for the substrate glucose 6- 
phosphate and the products glucose and phosphate [1,7,8]. 
Glucose-6-phosphatase ctivity has been shown to in- 
crease under a variety of conditions where hepatic glucose 
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output increases, e.g., starvation and diabetes [1,2,9]. Thy- 
roxine has been reported to increase the overall metabolic 
rate (e.g., see [10] for review). There is also evidence in 
the literature of increased hepatic gluconeogenic capacity 
after thyroid hormone treatment (e.g., see [10-12]) as well 
as a wide variety of other effects on energy metabolism 
[10,13]. It seems likely, therefore, that thyroxine might 
also act on glucose-6-phosphatase. Early work (over 20 
years ago) studying the effects of thyroxine and/or tri- 
iodothyronine on metabolism, e.g., [9,14-21] indicated 
that it increased glucose-6-phosphatase ctivity. However, 
this early work on the effects of thyroxine on glucose-6- 
phosphatase is difficult to interpret as it was done before 
the demonstration that glucose-6-phosphatase is a com- 
plex, multicomponent system in the endoplasmic reticulum 
and because the studies were done under a wide variety of 
different conditions using different assay techniques. Re- 
cently we have demonstrated (Voice et al., submitted for 
publication) that the liver and kidney glucose-6-phos- 
phatase systems are regulated ifferently. We have there- 
fore carried out a kinetic analysis of both the liver and 
kidney glucose-6-phosphatase ystems in normal, 
adrenalectomised and hypophysectomised rats treated with 
thyroxine. The surgically altered animals were used be- 
cause they are obvious models to study the effects of 
thyroxine without counter regulation by the respective 
endogenous hormones. 
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2. Materials and methods 
2.1. Materials 
Glucose 6-phosphate (monosodium salt), histone 2AS 
and thyroxine were purchased from Sigma (Poole, UK). 
All other chemicals (AnalaR grade) were purchased from 
BDH (Poole, UK). 
2.2. Treatment of  animals 
Adult Wistar male and female rats (approx. 9 weeks of 
age) were used throughout. All animals had free access to 
food and water. Adrenalectomised and hypophysectomised 
animals were obtained from Charles River (Margate, UK) 
and were allowed five weeks recovery after the surgical 
procedures. Drinking water was supplemented with 0.9% 
sodium chloride for the adrenalectomised animals and 
0.5% sucrose/0.9% sodium chloride for the hypophysec- 
tomised animals. 
In hormone treated animals, 4 doses of 0.15 mg/100 g 
body weight thyroxine were administered at 24 h intervals 
by intraperitoneal injection. Animals were killed 30 min 
after the final injection and the livers removed. 
glucose-6-phosphatase ctivity of disrupted microsomes 
was assayed using substrates supplemented with 0.8 mg/ml  
histone 2AS [24]. Microsomes are isolated as a mixture of 
intact and disrupted vesicles and the proportion of intact 
vesicles in each preparation was quantified by measuring 
mannose-6-phosphatase activity, which is only measurable 
in disrupted structures [25]. All of the microsomal prepara- 
tions used were at least 90% intact. The intact values in 
this paper have been corrected for the contribution by 
disrupted structures as previously described [23], which 
eliminates the large errors in activity measurements which 
occur if even a small proportion of the vesicles are dis- 
rupted. Microsomal protein content was determined using 
the method Lowry as modified by Peterson [26]. Full 
kinetic analysis of the data was carried out using multiple 
non-linear egression programs on a BBC microcomputer 
[27]. Latency is defined in this paper as the percentage of 
glucose-6-phosphatase activity in disrupted microsomes 
which is not evident in intact microsomes. Blood glucose 
levels were determined using a Beckman glucose analyser. 
Glycogen levels were determined following the method of 
[28]. Statistical analysis was performed using Student's 
t-test as described in [29]. 
2.3. Microsome preparation 3. Results 
Microsomes were prepared from 10% tissue ho- 
mogenates in 0.25 M sucrose/5 mM Hepes (pH 7.4) as 
described in [22]. The microsomal pellets were resus- 
pended to a final protein concentration of approx. 20 
mg/ml ,  aliquoted and stored frozen at -70°C until use 
(within ! month). 
2.4. Enzyme assays 
Glucose-6-phosphatase activity was determined as in 
[23] using concentrations of glucose 6-phosphate of 1, 1.4, 
2, 2.6, 5 and 30 mM and 1 mM mannose 6-phosphate. The 
Glucose-6-phosphatase enzyme activity (Vma x) in dis- 
rupted microsomes i olated from normal male rat liver was 
not significantly changed by thyroxine treatment (Table 1). 
In contrast, thyroxine more than doubled glucose-6-phos- 
phatase enzyme activity in disrupted microsomes isolated 
from adrenalectomised and hypophysectomised male rat 
livers (Table 1). The K m of the glucose-6-phosphatase 
enzyme in disrupted liver microsomes was not signifi- 
cantly affected by thyroxine treatment in any of the prepa- 
rations (Table 1). Similar effects were also seen in dis- 
rupted microsomes isolated from female rat livers (e.g., in 
female hypophysectomised rats (n = 3) treated with thy- 
Table 1 
Effect of thyroxine treatment on normal, adrenalectomised an hypophysectomised male rat liver glucose-6-phosphatase activity 
Disrupted microsomes Disrupted microsomes Intact microsomes Intact microsomes Latency 
Vm~  (nmol/min per mg) K m (mM) Vm~  (nmol/min per mg) K m (mM) (%) 
Normal 
Control (n = 3) 241 ± 19 0.5 ± 0.1 152 _ 14 3.4 + 0.9 37 
Thyroxine (n = 3) 285+5 0.7+0.1 234_+21 * 2.8+0.7 18 
Adrenalectomy 
Control (n = 3) 171 + 10 0.4 + 0.1 109 ± 8 2.4 _ 0.5 36 
Thyroxine (n = 3) 383 ± 13 * * 0.8 ± 0.2 252 ± 8 ~ * 5.5 ± 1.2 34 
Hypophysectomy 
Control (n = 4) 140 __ 10 0.3 ± 0.1 90 _+ 10 3.5 ± 0.4 36 
Thyroxine(n=4) 416+_44 ** 0.5±0.2 227± 17 * 3.7±0.1 45 
Data are the mean + S.E. from at least hree different microsome preparations. * P < 0.05, * * P < 0.01 significantly different from corresponding control 
value. 
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Table 2 
Effect of thyroxine treatment on normal, adrenalectomised and hypophysectomised male rat kidney glucose-6-phosphatase activity 
Disrupted microsomes Disrupted microsomes Intact microsomes Intact microsomes Latency 
V,~x (nmol/min per mg) K~ (mM) Vm~  (nmol/min per mg) K,, (raM) (%) 
Normal 
Control (n = 3) 210 + 20 0.4 + 0.1 150 _-+- 10 4.2 + 0.9 29 
Thyroxine (n = 3) 283+5 ~ 0.6+0.1 142_+18 2.4+0.6 50 
Adrenalectomy 
Control (n = 3) 256 _+ 24 0.5 _+_ 0.1 160 + 10 3.4 + 1.9 38 
Thyroxine (n = 3) 384_+ 6 * * 0.7 _+ 0.1 235 + 8 * ~ 6.6 + 1.2 39 
H3pophysectomy 
Control (n = 4) 260 _+ 10 0.6 + 0.1 140 + 10 4.1 _+ 0.4 46 
Thyroxine (n = 4) 440 _+ 59 * 0.3 _+ 0.2 228 _+ 24 * 4.5 + 1.1 48 
Data are the mean + S.E. from at least three different microsome preparations. ~P < 0.05, * * P < 0.01 significantly different from corresponding control 
value. 
roxine the glucose-6-phosphatase activity (Vma x) in dis- 
rupted microsomes was increased 2.5-fold without signifi- 
cantly altering the Kin). 
Glucose-6-phosphatase system activity (Vma x) in intact 
microsomes isolated from normal male rat l iver was signif- 
icantly increased by thyroxine treatment, without a signifi- 
cant K m difference (Table 1). Glucose-6-phosphatase ac- 
tivity (Vma x) in intact microsomes isolated from adrenalec- 
tomised and hypophysectomised male rat livers was more 
than doubled by thyroxine treatment without significant 
increase in the K m (Table 1). Similar effects of  thyroxine 
were seen in intact microsomes isolated from female rat 
livers (e.g., in female hypophysectomised rats (n = 3) 
treated with thyroxine the glucose-6-phosphatase activity 
(Vma ×) in intact microsomes was increased 1.8-fold without 
significantly altering the Km). 
In kidney, thyroxine treatment increased the Vma x of 
glucose-6-phosphatase activity in disrupted microsomes in 
normal, adrenalectomised and hypophysectomised animals 
(Table 2). The K m of the glucose-6-phosphatase enzyme 
in disrupted kidney microsomes was not significantly af- 
fected by thyroxine treatment in any of  the preparations 
(Table 2). In intact kidney microsomes thyroxine treatment 
did not increase the glucose-6-phosphatase activity in nor- 
mal animals but caused a significant increase in both 
adrenalectomised and hypophysectomised animals (Table 
2). In all three cases, thyroxine treatment did not signifi- 
cantly alter the K m of glucose-6-phosphatase activity in 
intact kidney microsomes (Table 2). 
Thyroxine treatment did not significantly change blood 
glucose levels of  normal, adrenalectomised and hypophy- 
sectomised rats (Table 3). Thyroxine dramatically lowered 
l iver glycogen levels in normal and adrenalectomised ani- 
mals and caused a smaller, not quite statistically significant 
decrease in l iver g lycogen in hypophysectomised rats. In 
kidney, thyroxine significantly decreased glycogen levels 
in normal rats but not in adrenalectomised and hypophy- 
sectomised rats (Table 3). 
4. Discussion 
The complexity of  the glucose-6-phosphatase system, 
its dependence on microsomal intactness and the problem 
that individual components of  the system are inhibited 
differently by commonly  used buffers and the detergents 
Table 3 
Effect of thyroxine treatment on blood glucose and liver glycogen levels in normal, adrenalectomised and hypophysectomised rats 
Blood glucose Liver glycogen Kidney glycogen 
(mM) (/zg/mg microsomal protein) (/xg/mg microsomal protein) 
Normal 
Control (n = 3) 4 _+ 1 532 + 17 396_+ 19 
Thyroxine (n = 3) 7 + 2 69 + 8 ~ * 128 -+- 48 * * 
Adrenalectomy 
Control (n = 3) 9 + 1 573 + 73 134 + 83 
Thyroxine(n=3) 9+ 1 153+56 ~ 160+ 12 
Hypophysectomy 
Control (n = 3) 5 + 1 704 + 103 216_+ 102 
Thyroxine (n = 3) 7 + 1 306 +_ 142 170 +_ 109 
Data are the mean +_ S.E. from at least hree different microsome preparations. * P < 0.05, * * P < 0.01 significantly different from corresponding control 
value~ 
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used to disrupt the microsomal membrane, means that 
great care has to be taken in experimental design and 
choice of assay conditions. Unfortunately, much of the 
previous work [9,14-21,30,3 l] on the effects of thyroxine 
on glucose-6-phosphatase wasdone before the information 
needed for optimum assay conditions was widely avail- 
able, e.g., see [23,32,33]. This unfortunately means that, 
for a variety of different reasons, it is difficult to interpret 
whether or not thyroxine does increase glucose-6-phos- 
phatase activity, e.g., [34] and whether, when changes have 
been reported, they were effects on transport systems or 
enzyme or whether they were merely due to decreased 
microsomal intactness. 
To ensure that we would detect both regulation of 
glucose-6-phosphatase expression and short term effects of 
thyroxine we administered thyroxine for four days and 
then killed the animals within a short time of the final 
thyroxine administration. We chose this regime because 
early work [17] had suggested that the maximal effects of 
thyroid hormones on liver microsomal enzymes were seen 
after 60 h. The significant decreases in liver and kidney 
glycogen content following thyroxine treatment of normal 
animals (Table 3) indicate that the amounts of thyroxine 
administered caused substantial effects on both liver and 
kidney carbohydrate metabolism. The lack of effect of 
thyroxine treatment on blood glucose levels is presumably 
caused at least in part by supplementation f the animals' 
drinking water (freely available) with sucrose. 
Glucose-6-phosphatase ctivity in intact microsomes i
a measure of the combined rate of glucose-6-phosphatase 
enzyme and the glucose 6-phosphate, phosphate and glu- 
cose transport proteins. In disrupted microsomes the sub- 
strates have free access to the enzyme, therefore only the 
activity of the glucose-6-phosphatase enzyme is measured. 
In isolated control liver and kidney microsomes the trans- 
port proteins are normally rate limiting. This means that 
the glucose-6-phosphatase ctivity in intact microsomes i
usually less than the activity in disrupted microsomes, 
consequently glucose-6-phosphatase ctivity in intact mi- 
crosomes is described as latent. It is therefore necessary to 
assay the glucose-6-phosphatase ctivity in both intact and 
disrupted microsomal vesicles to distinguish between the 
effects of hormones on the transport capacity and the 
hydrolytic activity of the glucose-6-phosphatase system. 
Thyroxine treatment of adrenalectomised and hypophy- 
sectomised male rats resulted in a more than 2-fold in- 
crease in the activity of the liver glucose-6-phosphatase 
enzyme in disrupted liver microsomes (Table 1), clearly 
demonstrating that thyroxine treatment increases the activ- 
ity of the hepatic glucose-6-phosphatase enzyme. In con- 
trast, there was not a significant increase in hepatic glu- 
cose-6-phosphatase enzyme activity in disrupted micro- 
somes following thyroxine treatment of normal male ani- 
mals (Table 1). Glucose-6-phosphatase ctivity in intact 
microsomes was significantly increased following thyrox- 
ine treatment without a significant K m change in normal, 
adrenalectomised and hypophysectomised male rat liver 
(Table 1). In normal animals where thyroxine has no effect 
on the activity of the glucose-6-phosphatase enzyme, the 
increased activity of the whole glucose-6-phosphatase sys-
tem in intact microsomes must be due to increased trans- 
port capacity. This is reflected by the decrease in latency 
(at Vma ×) seen following thyroxine treatment. It has been 
previously reported that in intact rat liver microsomes the 
rate-limiting step in G-6-P hydrolysis is the transport of 
G-6-P across the microsomal membrane via the transport 
protein TI [35], therefore the logical target for the effect of 
thyroxine treatment in normal animals must be T1, al- 
though a minor effect on the other transport proteins 
cannot be ruled out. In disrupted microsomes, the K m 
represents he K m of the G-6-Pase enzyme alone, whereas 
in intact microsomes the K~ reflects the combined contri- 
butions of the enzyme and the various associated transport 
mechanisms. It has been suggested that in intact rat liver 
microsomes with glucose 6-phosphate as substrate a major 
component of the K m of the system is the K~ of TI [35]. 
However the lack of change in K m of the intact system 
indicates that thyroxine treatment does not significantly 
lower the K m of G-6-P transport. 
In contrast, the latency of the glucose-6-phosphatase 
system is not decreased in adrenalectomised and hypophy- 
sectomised male rat liver after thyroxine treatment, indicat- 
ing that the enzyme is activated together with the transport 
systems by thyroxine treatment. Studies in female rats 
gave very similar responses to thyroxine to those seen in 
male animals, indicating that levels of sex hormones in 
adult animals do not significantly modulate the effect of 
thyroxine on the glucose-6-phosphatase system. 
Virtually nothing is known about the effects of thyrox- 
ine on glucose-6-phosphatase in kidney. We therefore also 
studied glucose-6-phosphatase activity in the kidney of the 
animals described above. Thyroxine increased glucose-6- 
phosphatase enzyme activity in normal adrenalectomised 
and hypophysectomised rat kidney microsomes although 
the increases were not as large as those seen in the 
adrenalectomised and hypophysectomised rat livers ( 
Tables 1 and 2). Glucose-6-phosphatase system activity in 
intact kidney microsomes was only increased by thyroxine 
treatment in adrenalectomised and hypophysectomised ani- 
mals. In thyroxine treated normal rat kidney, there is 
therefore an increase in the glucose-6-phosphatase enzyme 
activity without a concomitant increase in the transport 
capacity, which is reflected in the increased latency of the 
intact kidney microsomal glucose-6-phosphatase system. 
In contrast, in adrenalectomised and hypophysectomised 
rat kidney microsomes, the latency is not altered following 
thyroxine treatment, reflecting similar increases in both the 
enzyme activity and transport capacity of the system. 
The liver and kidney glucose-6-phosphatase systems 
were activated similarly by thyroxine in the surgically 
altered animals. In contrast, in normal rats, the glucose-6- 
phosphatase enzyme was the major site of thyroxine action 
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in kidney, whi le microsomal  transport  was the major  site 
of action in liver. This suggests that it is the counter  
regulat ion of  the l iver and k idney g lucose-6-phosphatase 
systems that is t issue specif ic rather than the effect of 
thyroxine itself. The fact that in di f ferent c i rcumstances 
thyroxine can change either the enzyme,  transport  systems 
or both explains the diff icult ies that are encountered when 
trying to interpret data f rom the previous l iterature, and 
determine the site of  action of thyroxine on the glucose-6- 
phosphatase system. The dif ferent effect of  thyroxine in 
the k idneys and l ivers of  normal  rats reinforces our previ-  
ous f indings (Voice et al., submitted for publ icat ion)  of  
t issue specif ic regulat ion of  g lucose-6-phosphatase.  
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